SPRY Key Statistics, Chart & Performance
The current stock price of SPRY is 11.605 USD. In the past month the price increased by 37.36%. In the past year, price increased by 2.22%.
SPRY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.36 | 406.77B | ||
| AMGN | AMGEN INC | 15.21 | 179.17B | ||
| GILD | GILEAD SCIENCES INC | 15.4 | 156.45B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.69 | 117.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.47 | 82.66B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.51 | 52.86B | ||
| INSM | INSMED INC | N/A | 37.76B | ||
| NTRA | NATERA INC | N/A | 32.31B | ||
| BIIB | BIOGEN INC | 10.56 | 25.92B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.48 | 22.14B | ||
| INCY | INCYTE CORP | 15.69 | 19.78B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About SPRY
Company Profile
ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. The company is headquartered in San Diego, California and currently employs 162 full-time employees. The company went IPO on 2020-12-04. The firm is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
Company Info
ARS PHARMACEUTICALS INC
11682 El Camino Real, Suite 300
San Diego CALIFORNIA US
Employees: 165
Phone: 18587719307
ARS PHARMACEUTICALS INC / SPRY FAQ
Can you describe the business of ARS PHARMACEUTICALS INC?
ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. The company is headquartered in San Diego, California and currently employs 162 full-time employees. The company went IPO on 2020-12-04. The firm is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
What is the stock price of ARS PHARMACEUTICALS INC today?
The current stock price of SPRY is 11.605 USD. The price increased by 5.21% in the last trading session.
Does SPRY stock pay dividends?
SPRY does not pay a dividend.
What is the ChartMill technical and fundamental rating of SPRY stock?
SPRY has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does ARS PHARMACEUTICALS INC belong to?
ARS PHARMACEUTICALS INC (SPRY) operates in the Health Care sector and the Biotechnology industry.
What is ARS PHARMACEUTICALS INC worth?
ARS PHARMACEUTICALS INC (SPRY) has a market capitalization of 1.15B USD. This makes SPRY a Small Cap stock.
What is the ownership structure of ARS PHARMACEUTICALS INC (SPRY)?
You can find the ownership structure of ARS PHARMACEUTICALS INC (SPRY) on the Ownership tab.
SPRY Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to SPRY. When comparing the yearly performance of all stocks, SPRY turns out to be only a medium performer in the overall market: it outperformed 63.79% of all stocks.
SPRY Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SPRY. SPRY scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SPRY Financial Highlights
Over the last trailing twelve months SPRY reported a non-GAAP Earnings per Share(EPS) of -0.84. The EPS decreased by -64.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.47% | ||
| ROE | -54.21% | ||
| Debt/Equity | 0.65 |
SPRY Forecast & Estimates
For the next year, analysts expect an EPS growth of -3608.8% and a revenue growth 341.52% for SPRY